Indication

Metastatic Epithelioid Hemangioendothelioma

1 clinical trial

1 product

Clinical trial

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma

Status: Completed, Estimated PCD: 2023-06-23

Product